Horizon Discovery Expands Screening Services
Horizon Discovery has announced that it has expanded its cell-based clustered regularly interspaced short palindromic repeats (CRISPR) screening services to include primary human B cells, which complements the T cell screening service.
Horizon Discovery has announced, in an April 3, 2020 press release, that it has expanded its cell-based clustered regularly interspaced short palindromic repeats (CRISPR) screening services to include primary human B cells, which complements the T cell screening service.
The new arrayed CRISPR knockout screening service for B cells will allow researchers the ability to identify genes that affect the function of B cells and examine how this might impact other types of immune cells. These capabilities are particularly aimed at use in infectious diseases, cancer, and auto-immune disorders, such as COVID-19, Burkitt’s lymphoma, and multiple sclerosis, respectively.
“The interest in harnessing the immune system for effective therapies continues to grow, with the global cell therapy market predicted to reach $8.21 billion by 2025 [according to market research],” said Terry Pizzie, CEO, Horizon Discovery, in the press release. “Expanding our services to encompass screening of both primary T and B cells is another example of our commitment to apply decades of gene editing experience in support of drug discovery and development for the treatment of human disease.”
Source: Horizon Discovery
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 2nd 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
